Sirius bridges lab and plant Full cycle and safety rules

Oct 5

Shmeleva identifies the laboratory-to-production gap as the main bioeconomy barrier and proposes universities as places for prototyping, scaling, controlled trials and professional training. She describes Sirius's educational centre, lyceum, university, laboratories and innovation centre with 113 resident companies as a full-cycle model. She says a pilot pharmaceutical facility with R-Pharm is being created and initial steps taken toward an agricultural testing cluster with the Agriculture Ministry. She proposes science-based safety requirements for crop genome editing and industrial microbiology, explicitly rejecting simple regulatory relaxation or exemptions. She calls for chief designers responsible for the entire idea-to-product chain and describes real industry tasks for students. She says the integrator model is being scaled nationally; the facilities and regulatory measures are not all described as completed.

At BIOPROM, Shmeleva presents Sirius's university, laboratories, education and innovation infrastructure as a bridge from scientific ideas through controlled trials and scaling to industry. She cites 113 resident companies, a pharmaceutical pilot being created with R-Pharm and early agricultural-cluster work. She emphasizes responsible chief designers and real industry tasks. Vremya's shorter excerpt describes the same education-to-implementation-and-regulation cycle. Planned facilities are distinguished from operating infrastructure.